Format

Send to

Choose Destination
Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Author information

1
Vanderbilt-Ingram Cancer Center/Vanderbilt University Medical Center, TN;
2
University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;
3
H. Lee Moffitt Cancer Center, Tampa, FL;
4
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;
5
Tufts University Medical Center, Boston, MA;
6
Weill Cornell Medical College, New York, NY;
7
Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Université Paris Diderot, Paris, France;
8
Institut Gustave Roussy, Villejuif, France;
9
Mayo Clinic Cancer Center, Scottsdale, AZ;
10
MD Anderson Cancer Center, Houston, TX;
11
Hospital Universitario y Politecnico La Fe, Valencia, Spain;
12
University of Freiburg, Germany;
13
The August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain;
14
University of Düsseldorf, Düsseldorf, Germany; and.
15
University of Southampton and Wessex Regional Genetics Laboratory, Salisbury, United Kingdom.

Abstract

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.

PMID:
25624319
PMCID:
PMC4915792
DOI:
10.1182/blood-2014-10-607341
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center